Published: 1 December 2020
Author(s): Xavier Kurz, Peter Arlett, Hans-Georg Eichler, Alexis Nolte, Sabine Straus, Guido Rasi
Issue: January 2021
Section: Commentary

In ETNA VTA Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries, Cohen et al. report the results of a non-interventional drug utilisation study of edoxaban and conclude that these data reinforce the largely appropriate use of edoxaban in clinical practice [1]. This report is part of the ETNA-VTA Europe post-authorisation safety study (PASS) included by the pharmaceutical company in the Risk Management Plan (RMP) of the product at the time of its marketing authorisation application [2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.